Articles Posted in Dangerous Drugs

A personal injury is any kind of accident where you are injured. If you have an accident and feel another party is at fault, you may decide to file what is called a personal injury claim in order to be compensated for damages that may occur from medical or emotional costs associated with the accident.

There are many types of personal injury claims, and while you can file a personal injury claim for just about anything, the most common types of claims are those that involve car accidents, work related injuries, slip and fall accidents, accidents in your home and holiday accidents. Others include product liability claims such as when you are injured from a defective product that you have purchased.

When you file a personal injury claim, you are asked to describe the accident, and provide a dollar amount that you think is suitable compensation. This can include medical and dental bills, money lost due to time missed from not being able to work, or even emotional damage if you can prove your accident caused you emotional or psychological stress.

Attorneys across the U.S. are starting to advertise for and are being contacted by people who took the diabetes drug Actos® and now have bladder cancer.

While France has pulled Actos® off of the market and Germany has recommended to physicians that no new patients begin the drug, in the U.S., Actos® is still being sold with only added warnings to the patient information labels. Physicians have also been give the warning that they should not prescribe Actos® to patients who have bladder cancer or who have had bladder cancer.

Actos® came to the market 10 years ago and it seemed like a perfect Type II diabetes drug because it helped control blood sugar and only had to be taken once a day. For many patients, it meant they would not have to inject insulin.

The problem with Actos® is no one really understood the effects it would have on the body when taken for 5 or 10 years.

The FDA has just released their analysis of five years of data of a 10-year Actos® safety study that began in 2002. The conclusion is that, while the overall number of bladder cancer cases are small, it appears that there are an extra 28 cases a year for every 100,000 people who have taken Actos®. The conclusion is that the risk of risk of bladder cancer was 40% higher for those patients who have taken Actos® for a year or more.

In recent months, personal injury attorneys across the U.S. have been contacted by patients with bladder cancer. Many bladder cancer patients have had to undergo several surgeries and chemotherapy.

The personal injury lawyers at The Farber Law Group feels that Takeda Pharmaceuticals either knew or should have known about the serious risk of bladder cancer. We will work hard to investigate Takeda’s actions and we will do all that we can to help bladder cancer patients who took Actos®.

Related Posts:

FDA announces changes to Actos® diabetes medication labeling

What is the link between bladder cancer and Actos?

French news announces suspension of diabetes drug, Actos Competact
Continue reading

The U.S. Food and Drug Administration issued a notice to the public that they have approved updating drug labels of medications including pioglitazone, including Actos®. The added information states that, in patients using pioglitazone for more than one year, there can be an increased risk of bladder cancer.

The new wording for the label can be found in the Warnings and Precautions section of medicines containing pioglitazone. The patient Medication Guide will also be revised to indicate the bladder cancer association.

The FDA made this action after review a five-year interim analysis of a ten-year epidemiological study which found an increased risk of bladder cancer in patients who had taken Actos® the longest and those who had taken it at higher dosages.

It is interesting to note that the FDA did not suspend the sale of Actos® in this country though France has suspended the use of pioglitazone and Germany has recommended that physicians do not prescribe any new patients with the medication.

The FDA recommends:

  • Patients with bladder cancer should not take Actos®
  • Patients with a history of bladder cancer previously should decide whether the benefits of the drug outweigh the risk.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We represent people who have been injured due to faulty medical devices and dangerous drugs, including Actos.

Related Posts:

What is the link between bladder cancer and Actos?

French news announces suspension of diabetes drug, Actos Competact

Diabetes drug, Actos, recalled in the French market
Continue reading

Recently the U.S. Food and Drug Administration (FDA) issued warnings that Actos (pioglitazone), a drug to treat Type II Diabetes, may be linked to bladder cancer. The risk is even higher for those patients who take the medication at a higher dosage over an extended period of time according to The Wall Street Journal. Actos is one of several drugs that have contains pioglitazone.

Pioglitazone has been pulled from drug store shelves in France and Germany has recommended not prescribing medication containing pioglitazone to new patients after an epidemiological study by the Caisse National d’Assurance Maladie but it remains on drug store shelves here in the United States.

Takeda Pharmaceuticals, the manufacturer of Actos, has agreed to sponsor a study which looks at link between Actos and bladder cancer.

The FDA’s mid-review of a ten-year epidemiological study of 193,000 patients over the age of 40 with type II diabetes found that the patients who took Actos for more than 12 months had a 40 percent higher risk of developing bladder cancer.

Signs and symptoms of bladder cancer include blood in the urine which may or may not be visible to the eye or detected by microscopic investigation. Other symptoms include painful urination or urgency in urination.

The Farber Law Group, a personal injury law firm in Western Washington, is currently representing people who have bladder cancer and have taken Actos. Fill out our Contact Form if you would like more information.

Related Posts:

French news announces suspension of diabetes drug, Actos Competact

Diabetes drug, Actos, recalled in the French market
Continue reading

The Director General of the Agency of Medicines in France (Afssaps) announced that the diabetes drug Actos Competact, sold as Actos (pioglitazone) in the United States, has been suspended for sale in France because it is responsible for a significant increase in bladder cancer in men according to the French newspaper Le Monde.

Afssaps held a vote and members of the commission voted 25 aye and one abstaining to suspend the sale of the drug after a study by the National Health Insurance (CNAM) found

“a statistically significant association” between exposure to pioglitazone, an antidiabetic medication currently on the hot seat, and the incidence of bladder cancer.”

According to LeMonde, the study shows that the risk of bladder cancer increased by 22% when using Actos. The study showed that the risk increases up to 75% when patients were treated with a high dose. The study followed 1.5 million diabetics, 155,000 who had taken pioglitazone.

Actos was first sold in Europe in 200 and approximately 230,000 patients were treated with the drug in France. The Afssaps warns, “Doctors should no longer prescribe the medicines containing pioglitazone.”

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a personal injury law firm and we represent people who are injured due to dangerous drugs, including Actos.

Related Posts:

Diabetes drug, Actos, recalled in the French market

FDA warns that Actos® increases the chance of bladder cancer in patients who have taken the medication for more than one year
Continue reading

Takeda Phamaceutical Co., along with its French subsidiary, Laboratories Takeda, has agreed to withdraw Actos® (pioglitazone) and Competact (pioglitazone and metformin) because of concerns about an increased risk of bladder cancer with the drug.

The two medications are used to treat type II mellitus diabetes which is a form of non-insulin-dependent diabetes. In the U.S., the drug is sold under the name Actos®. Beginning in June of this year, the U.S. Food and Drug Administration added extra warning labels to products containing pioglitazone.
seattle actos bladder cancer lawyer
It appears that France is jumping ahead of the United States by making changes to their drug regulations including ensuring that medications sold in France are safe and also improving patient education and information regarding the risks of medication.

The decision to remove Actos® from the French market came after a study in May by Italian researchers who found a connection between Actos® and bladder cancer.

Some bladder cancer patients in the United States may file lawsuits against Takeda Pharmaceutical for failing to adequately test the drug or warn patients about a bladder cancer risk.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a personal injury law firm with more than 40 years experience representing people who have become ill due to dangerous drugs, including Actos® and drugs containing Pioglitazone.
Continue reading

A federal court jury awarded Douglas Ray, 67, $212 million in damages against Allergan Inc. after Ray suffered permanent brain damage after he was injected with Botox to treat hand tremors in 2007. This case sets a record for an award in a Botox injury case.

The jury awarded Ray $12M in compensatory damages and $200M in punitive damages. Compensatory damages are damages which compensates a person for their actual losses including pain and suffering, expenses and economic losses. Punitive damages combine both punishment and the setting of public example. These damages are awarded when a defendant’s action was malicious, violent, oppressive, fraudulent or grossly reckless.

Ray’s lawsuit claimed that Allergan failed to warn his doctor about risks involved of using Botox for “off-label” use. Off-label use is when a physician prescribes an otherwise approved medication for other than their approved indications.

The jury in this case felt that Allergan had heavily marketed Botox to physicians for other than reducing wrinkles.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a Seattle personal injury law firm and we represent clients with their product liability cases.

Jury orders Allergan to pay $212 mln in Botox case
Reuters News Service
Related Posts:

Product liability lawsuit filed in Connecticut because of failed DePuy hip implant

Denture wearers file lawsuit against makers of PoliGrip and Fixodent

Jury awards woman with Fosamax injury $8 million

Continue reading

The Federal Drugs Administration (FDA) has issued a health warning saying that
bisphosphonate drugs such as Fosamax© and Boniva are linked to rare fractures of the femur. The fractures occurred right below the hip joint and are extremely rare.

The FDA has issued a brochure Possible Fracture Risk With Osteoporosis Drugs to patients and physicians which warns of the femoral fracture. The FDA says that the fractures may be related to prolonged use of the medication, five years or more.

Biophoshonates have been prescribed since 1995 to prevent and treat osteoporosis. The FDA says it is not clear if the drugs are the cause of the bone fractures. For now, they are advising patients and physicians to pay attention to symptoms that might occur prior to a fracture including a dull or aching pain in the thigh or hip.

A patient who suffers this type of fracture might have a valid medical malpractice claim if their physician failed to warn them of the side effects and left them on the medication without warning them of potential risks.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We represent people who have suffered serious injury due to dangerous products and also victims of medical malpractice. With our help, you may recover compensation for your damages including pain and suffering.

Related Posts:

Jury awards woman with Fosamax injury $8 million

Seattle Group Health study links osteoporosis drug to heart problems
Continue reading

Merck & Co. the manufacturer of Fosamax, an osteoporosis drug, has been ordered to pay Shirley Boles, 72, $8 million dollars finding that her jaw disease, osteonecrosis, was caused by taking Fosamax.

The crux of Boles’ suit is that Merck failed to warn doctors and patients that the drug might effect the flow of blood to the jaw, causing jawbone-tissue death. In finding against Merck, jurors found that Fosamax is defectively designed and unreasonably dangerous according to Bole’s attorney.

Merck faces hundreds of product liability lawsuits because of allegations that the drug caused the jaw-destroying condition.

Both The Seattle Times and The Seattle Post Intelligencer report today that Fosamax©, a medication to treat osteoporosis, appears to double a woman’s chance of having atrial fibrillation, a sometimes serious heart condition.

Fosamax© is manufactured by Merck & Co. A generic version, alendronate, was approved by the Federal Drug Administration in 2008. Fosamax© has also been linked to another serious condition, osteoncrosis of the jaw, also known as jaw necrosis or jaw death. Osteonecrosis can cause parts of the jawbone to deteriorate, causing an extremely painful condition that can lead to jaw removal.

The Seattle, Washington study which was published in the Archives of Internal Medicine was done by Group Health in Seattle and the University of Washington. The study, which followed 719 women with atrial fibrillation, compared them with 966 women who did not have the condition. The study found that the women who had taken Fosamax©, had an 86% higher incidence of the condition.

Contact Information